Search tips
Search criteria 


Logo of jmedtoxspringer.comThis journalToc AlertsSubmit OnlineOpen ChoiceThis journal
J Med Toxicol. 2010 June; 6(2): 165–167.
Published online 2010 March 30. doi:  10.1007/s13181-010-0067-9
PMCID: PMC2919685

Hemodialysis Complications of Hydroxocobalamin: A Case Report


Hydroxocobalamin is a new antidote approved by the FDA for the treatment of cyanide poisoning. Our report describes a patient with cyanide poisoning who survived after treatment with hydroxocobalamin and complications we encountered with hemodialysis. A 34-year-old female presented to the emergency department after a syncopal event and seizures. Her systolic blood pressure was 75 mmHg, her QRS complex progressively widened, and pulses were lost. She was intubated and resuscitated with fluids, sodium bicarbonate for her QRS widening and vasopressors. Venous blood gas demonstrated a pH of 6.36 with an O2 saturation of 99%. Due to the acidemia with a normal pulse oximetry, simultaneous venous and arterial blood gases were obtained. Venous gas demonstrated a pH of 6.80 with a PO2 of 222 mmHg, an O2 saturation of 99%. The arterial blood gas showed a pH of 6.82, a PO2 518 mmHg, an O2 saturation of 100%. Cyanide was suspected and hydroxocobalamin and sodium thiosulfate were given. Within 40 min of hydroxocobalamin administration, vasopressors were discontinued. Initially, nephrology attempted dialysis for metabolic acidosis; however, the dialysis machine repeatedly shut down due to a “blood leak”. This was an unforeseen effect attributed to hydroxocobalamin. Cyanide level, drawn 20 min after the antidote was completed, was elevated at 22 mcg/dL. Her urinary thiocyanate level could not be analyzed due to an “interfering substance”. Hydroxocobalamin is an effective antidote. However, clinicians must be aware of its effects on hemodialysis machines which could delay the initiation of this important treatment modality in the severely acidemic patient.

Keywords: Hydroxocobalamin, Hemodialysis, Cyanide

Full Text

The Full Text of this article is available as a PDF (95K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Morocco AP. Cyanides. Crit Care Clin. 2005;21(4):691–705. doi: 10.1016/j.ccc.2005.06.002. [PubMed] [Cross Ref]
2. Hall AH, Rumack BH. Clinical toxicology of cyanide. Ann Emerg Med. 1986;15(9):1067–1074. doi: 10.1016/S0196-0644(86)80131-7. [PubMed] [Cross Ref]
3. The Food and Drug Administration. Accessed January 28, 2009.
4. Hall AH, Rumack BH. Hydroxocobalomin/sodium thiosulfate as a cyanide antidote. J Emerg Med. 1987;5(2):115–121. doi: 10.1016/0736-4679(87)90074-6. [PubMed] [Cross Ref]
5. DesLauriers CA, Burda AM, Wahl M. Hydroxocobalamin as a cyanide antidote. Am J Ther. 2006;13(2):161–165. doi: 10.1097/01.mjt.0000174349.89671.8c. [PubMed] [Cross Ref]
6. Curry SC, Connor DA, Raschke RA. Effect of the cyanide antidote hydroxocobalamin on commonly ordered serum chemistry studies. Ann Emerg Med. 1994;24(1):65–67. doi: 10.1016/S0196-0644(94)70164-4. [PubMed] [Cross Ref]
7. Uhl W, Nolting A, Golor G, Rost KL, Kovar A. Safety of hydroxocobalamin in healthy volunteers in a randomized, placebo-controlled study. Clin Toxicol (Phila) 2006;44(Suppl 1):17–28. [PubMed]
8. Pamidi PV, DeAbreu M, Kim D, Mansouri S. Hydroxocobalamin and cyanocobalamin interference on co-oximetry based hemoglobin measurements. Clin Chim Acta. 2009;401(1–2):63–67. doi: 10.1016/j.cca.2008.11.007. [PubMed] [Cross Ref]
9. Lee J, Mukai D, Kreuter K, Mahon S, Tromberg B, Brenner M. Potential interference by hydroxocobalamin on cooximetry hemoglobin measurements during cyanide and smoke inhalation treatments. Ann Emerg Med. 2007;49(6):802–805. doi: 10.1016/j.annemergmed.2006.11.016. [PubMed] [Cross Ref]
10. Misra M. The basics of hemodialysis equipment. Hemodial Int. 2005;9(1):30–36. doi: 10.1111/j.1492-7535.2005.01115.x. [PubMed] [Cross Ref]

Articles from Journal of Medical Toxicology are provided here courtesy of Springer